Research graph
References from Statin–Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-κB Inhibition. Local targets link to admitted publications; unresolved targets remain external evidence.
Metabolic Dysfunction–Associated Steatotic Liver Disease and Metabolic Dysfunction–Associated Steatohepatitis–Related Fibrosis: Therapeutic Options and Approaches to Treatment
10.1146/annurev-med-050324-124753 · 2026 · External reference
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review
10.1001/jama.2025.19615 · 2026 · External reference
Metabolic dysfunction-associated steatotic liver disease (MASLD): A systemic disease with a variable natural history and challenging management
10.37349/emed.2025.1001281 · 2025 · External reference
Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches
10.1111/jgh.12212 · 2013 · External reference
Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver
10.1172/jci82204 · 2015 · External reference
Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation
10.1194/jlr.m700505-jlr200 · 2009 · External reference
Changes in Key Mitochondrial Lipids Accompany Mitochondrial Dysfunction and Oxidative Stress in NAFLD
10.1155/2021/9986299 · 2021 · External reference
Molecular targets regulating endoplasmic reticulum-mitochondria crosstalk for NAFLD treatment
2021 · External reference
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
2024 · External reference
The therapeutic landscape of non-alcoholic steatohepatitis
10.1111/liv.13270 · 2017 · External reference
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline
10.7326/m14-0126 · 2014 · External reference
Pleiotropic Effects of Statins on the Cardiovascular System
10.1161/circresaha.116.308537 · 2017 · External reference
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
10.1056/nejmoa1410489 · 2015 · External reference
2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
10.1093/eurheartj/ehz455 · 2020 · External reference
Mechanisms for the anti-inflammatory effects of statins
10.1097/mol.0b013e3283453e41 · 2011 · External reference
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins
10.1136/gutjnl-2014-308338 · 2015 · External reference
10.1371/journal.pone.0076538
10.1371/journal.pone.0076538 · External reference
Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia
10.1161/01.cir.0000068312.21969.c8 · 2003 · External reference
Increasing Doses of Simvastatin Versus Combined Ezetimibe/Simvastatin:Effect on Circulating Endothelial Progenitor Cells
10.1177/1074248413489771 · 2013 · External reference
10.1186/s12916-022-02288-2
10.1186/s12916-022-02288-2 · External reference
Resmetirom: The first approved therapy for treating metabolic dysfunction associated steatohepatitis
10.1080/14656566.2025.2478917 · 2025 · External reference
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
10.1111/liv.15930 · 2024 · External reference
10.1371/journal.pone.0132315
10.1371/journal.pone.0132315 · External reference
Nonglucuronidated Ezetimibe Disrupts CD13- and CD64-Coassembly in Membrane Microdomains and Decreases Cellular Cholesterol Content in Human Monocytes/Macrophages
10.1002/cyto.a.23772 · 2019 · External reference
Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model
10.1155/2019/3201873 · 2019 · External reference
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH
10.1194/jlr.m053785 · 2015 · External reference
Molecular mechanisms in thioacetamide-induced acute and chronic liver injury models
10.1016/j.etap.2023.104093 · 2023 · External reference
Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids
10.1016/j.toxlet.2019.11.005 · 2020 · External reference
10.3390/ijms232415791
10.3390/ijms232415791 · External reference
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review
10.1001/jama.2025.19615 · ExternalCitation · doi-reference
Nonglucuronidated Ezetimibe Disrupts CD13- and CD64-Coassembly in Membrane Microdomains and Decreases Cellular Cholesterol Content in Human Monocytes/Macrophages
10.1002/cyto.a.23772 · ExternalCitation · doi-reference
Molecular mechanisms in thioacetamide-induced acute and chronic liver injury models
10.1016/j.etap.2023.104093 · ExternalCitation · doi-reference
Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids
10.1016/j.toxlet.2019.11.005 · ExternalCitation · doi-reference
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
10.1056/nejmoa1410489 · ExternalCitation · doi-reference
Resmetirom: The first approved therapy for treating metabolic dysfunction associated steatohepatitis
10.1080/14656566.2025.2478917 · ExternalCitation · doi-reference
2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
10.1093/eurheartj/ehz455 · ExternalCitation · doi-reference
Mechanisms for the anti-inflammatory effects of statins
10.1097/mol.0b013e3283453e41 · ExternalCitation · doi-reference
Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches
10.1111/jgh.12212 · ExternalCitation · doi-reference
The therapeutic landscape of non-alcoholic steatohepatitis
10.1111/liv.13270 · ExternalCitation · doi-reference
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
10.1111/liv.15930 · ExternalCitation · doi-reference
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins
10.1136/gutjnl-2014-308338 · ExternalCitation · doi-reference
Metabolic Dysfunction–Associated Steatotic Liver Disease and Metabolic Dysfunction–Associated Steatohepatitis–Related Fibrosis: Therapeutic Options and Approaches to Treatment
10.1146/annurev-med-050324-124753 · ExternalCitation · doi-reference
Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model
10.1155/2019/3201873 · ExternalCitation · doi-reference
Changes in Key Mitochondrial Lipids Accompany Mitochondrial Dysfunction and Oxidative Stress in NAFLD
10.1155/2021/9986299 · ExternalCitation · doi-reference
Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia
10.1161/01.cir.0000068312.21969.c8 · ExternalCitation · doi-reference
Pleiotropic Effects of Statins on the Cardiovascular System
10.1161/circresaha.116.308537 · ExternalCitation · doi-reference
Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver
10.1172/jci82204 · ExternalCitation · doi-reference
Increasing Doses of Simvastatin Versus Combined Ezetimibe/Simvastatin:Effect on Circulating Endothelial Progenitor Cells
10.1177/1074248413489771 · ExternalCitation · doi-reference
10.1186/s12916-022-02288-2
10.1186/s12916-022-02288-2 · ExternalCitation · doi-reference
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH
10.1194/jlr.m053785 · ExternalCitation · doi-reference
Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation
10.1194/jlr.m700505-jlr200 · ExternalCitation · doi-reference
10.1371/journal.pone.0076538
10.1371/journal.pone.0076538 · ExternalCitation · doi-reference
10.1371/journal.pone.0132315
10.1371/journal.pone.0132315 · ExternalCitation · doi-reference
10.3390/ijms232415791
10.3390/ijms232415791 · ExternalCitation · doi-reference
Metabolic dysfunction-associated steatotic liver disease (MASLD): A systemic disease with a variable natural history and challenging management
10.37349/emed.2025.1001281 · ExternalCitation · doi-reference
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline
10.7326/m14-0126 · ExternalCitation · doi-reference
